Reappraisal of autologous stem cell transplantation for transformed indolent lymphoma in the bendamustine era-Reference-Cited by-同舟云学术

Reappraisal of autologous stem cell transplantation for transformed indolent lymphoma in the bendamustine era

Published:2024-08-20 Issue: Volume: Page:
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Stewart Colin^ORCID,Owen Carolyn,Shafey Mona,Perry Sarah,Sterrett Russell,Peters Anthea^ORCID,Duggan Peter^ORCID,Chua Neil,Stewart Douglas,Puckrin Robert

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41409-024-02399-9.pdf

Reference12 articles.

1. Federico M, Caballero Barrigón MD, Marcheselli L, Tarantino V, Manni M, Sarkozy C, et al. Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis. Lancet Haematol. 2018;5:e359–67.

2. Wang Y, Link BK, Witzig TE, Maurer MJ, Allmer C, King RL, et al. Impact of concurrent indolent lymphoma on the clinical outcome of newly diagnosed diffuse large B-cell lymphoma. Blood. 2019;134:1289–97.

3. Link BK, Maurer MJ, Nowakowski GS, Ansell SM, Macon WR, Syrbu SI, et al. Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic specialized program of research excellence molecular epidemiology resource. J Clin Oncol. 2013;31:3272–8.

4. Ban-Hoefen M, Vanderplas A, Crosby-Thompson AL, Abel GA, Czuczman MS, Gordon LI, et al. Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database. Br J Haematol. 2013;163:487–95.

5. Méndez M, Torrente M, Sánchez-Beato M, González-Rincón J, Royuela A, Gómez-Codina J, et al. Transformed follicular lymphoma in the rituximab era: A report from the Spanish Lymphoma Oncology Group. Hematol Oncol. 2019;37:143–50.